MedTrace Logo

Advancing Tobacco Use Treatment for African American Smokers

NCT02360631 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2020-07-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine whether or not providing Chantix (varenicline) will help African American smokers quit smoking.

Conditions

  • Smoking Cessation

Interventions

DRUG

Chantix

A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.

DRUG

Placebo

Health education counseling will be provided to all participants.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Lisa Sanderson Cox, PhD

    lead OTHER

Principal Investigators

  • Lisa Sanderson Cox, PhD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-29
Primary Completion
2018-07-12
Completion
2018-07-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02360631 on ClinicalTrials.gov